Red Queen Therapeutics
Latest round
- Series A
Last raised
- Oct 2021
Total raised
- $5M
Investors
- 1
About Red Queen Therapeutics
Red Queen Therapeutics, Inc.Founded in Cambridge, US, Red Queen Therapeutics, Inc. specializes in antiviral therapeutics. The company has undergone no major pivots in its business strategy.Red Queen Therapeutics specializes in the development of antiviral therapeutics utilizing a proprietary stapled lipopeptide platform technology. This platform is designed to block virus-cell fusion, effectively preventing the entry of enveloped viruses into human cells, thereby addressing a broad spectrum of virus-borne illnesses, such as COVID-19, influenza, respiratory syncytial virus (RSV), and others. Their lead product, RQ-01, has been evaluated in Phase 1 clinical trials and has demonstrated promising results in terms of safety and accelerated viral clearance in patients with COVID-19. The therapies are intended for use in various geographical markets, particularly in North America and Europe, and are aimed at healthcare providers, hospitals, and clinics that cater to patients at risk of severe viral infections.Red Queen Therapeutics' revenue model is primarily structured around partnerships and direct sales of their antiviral products to healthcare providers and institutions. The company engages in clinical trial collaborations and licensing agreements, which facilitate the development and commercialization of its therapeutic agents. Revenue generation may involve both upfront payments and milestone-based royalties associated with the successful progression of its products through clinical stages. The flagship product, RQ-01, alongside other pipeline candidates, is positioned for eventual market entry, with pricing strategies potentially reflecting the innovative nature of its lipopeptide therapies.In October 2021, Red Queen Therapeutics, Inc. Future growth initiatives include the development of new antiviral products and expansion into additional markets, particularly focusing on regions in North America and Europe by the end of 2023.
Who invested in Red Queen Therapeutics
1 investor across 1 round
See all investors in Red Queen Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 13, 2021
Amount
$5M
Investors
Questions about Red Queen Therapeutics
Who invested in Red Queen Therapeutics?
Red Queen Therapeutics has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Red Queen Therapeutics raised?
Red Queen Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Red Queen Therapeutics last raise money?
Red Queen Therapeutics's most recent round on record is a Series A, in Oct 2021.
What does Red Queen Therapeutics do?
Red Queen Therapeutics is a biotechnology company.
Where is Red Queen Therapeutics headquartered?
Red Queen Therapeutics is headquartered in Cambridge, US.
Which VCs invest in companies like Red Queen Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Red Queen Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Red Queen Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.